Trial Profile

Phase 2a randomized, double-blind, placebo-controlled, dose-finding study of APEX-002 for post-traumatic stress disorder

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Post-traumatic stress disorders
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Nov 2022 According to a Apex Laboratories media release, the company has received approval from Health Canada for this study. This approval comes by way of a No Objection Letter (NOL) from Health Canada received on October 24th, 2022.
04 Mar 2022 According to a Apex Laboratories media release, the company has receipt a No Objection Letter (NOL) from Health Canada regarding its phase 2a Clinical Trial Application ("CTA") protocol APEX-002-A01-01
14 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com